Specialty Chemicals company Tatva Chintan Pharma Chem announced Q2FY26 results Revenue from Operations: Rs 1,235 million compared to Rs 835 million during Q2FY25, change 48%. EBIDTA: Rs 222 million compared to Rs 56 million during Q2FY25, change 298%. EBIDTA Margin: 18.0% for Q2FY26. PAT: Rs 99 million compared to Rs -7 million during Q2FY25. PAT Margin: 8.0% for Q2FY26. Result PDF